Holen Sie sich die Stockscreener-App
1.52
3.80%
-0.06
Handel nachbörslich:
1.51
-0.01
-0.66%
Schlusskurs vom Vortag:
$1.58
Offen:
$1.59
24-Stunden-Volumen:
1.07M
Relative Volume:
0.57
Marktkapitalisierung:
$93.08M
Einnahmen:
$5.03M
Nettoeinkommen (Verlust:
$-185.41M
KGV:
-0.4919
EPS:
-3.09
Netto-Cashflow:
$-139.79M
1W Leistung:
-3.80%
1M Leistung:
-53.80%
6M Leistung:
-87.33%
1J Leistung:
-90.12%
1-Tages-Spanne:
$1.50
$1.61
1-Wochen-Bereich:
$1.38
$1.68
52-Wochen-Spanne:
$1.26
$16.52
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Firmenname
Pliant Therapeutics Inc
Sektor
Branche
Telefon
650-481-6770
Adresse
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie PLRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.52 | 93.08M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-04 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2025-03-04 | Herabstufung | Needham | Buy → Hold |
| 2025-03-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-02-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-02-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-04-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-07 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Outperform |
| 2022-05-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-20 | Eingeleitet | BTIG Research | Buy |
| 2021-04-05 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Cowen | Outperform |
| 2020-06-29 | Eingeleitet | Needham | Buy |
| 2020-06-29 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten
Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor - San Francisco Business Times
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - The Malaysian Reserve
Pliant Therapeutics Signs Shareholder Rights Agreement -March 13, 2025 at 08:32 am EDT - Marketscreener.com
Pliant Therapeutics adopts shareholder rights plan - Investing.com India
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement to Protect Shareholder Interests - Nasdaq
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement - Bluefield Daily Telegraph
Pliant Therapeutics Shields Against Hostile Takeover with Strategic Rights Plan - StockTitan
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant ... - Bluefield Daily Telegraph
Pliant dives 49% as it abandons phase 2 trial of bexotegrast for IPF - MSN
Pliant Therapeutics (NASDAQ:PLRX) Cut to “Hold” at Leerink Partnrs - Defense World
Needham Downgrades Pliant Therapeutics (MUN:9PT) - Nasdaq
If You Don’t Bullish On Pliant Therapeutics Inc (NASDAQ: PLRX) Now, You’ll Regret Your Decision Later - Stocks Register
Pliant halts lung fibrosis trial amid safety concerns - The Pharma Letter
Pliant Therapeutics (NASDAQ:PLRX) Price Target Cut to $3.00 by Analysts at Royal Bank of Canada - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Cut to Market Perform at Leerink Partners - MarketBeat
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Pliant Therapeutics - MENAFN.COM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc- PLRX - PR Newswire
Leerink Partners Downgrades Pliant Therapeutics (PLRX) - MSN
Pliant Therapeutics stock tumbles amid IPF trial cancellation - MSN
Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future - Benzinga India
Hold Rating on Pliant Therapeutics Amid Trial Discontinuation and Safety Concerns - TipRanks
Pliant downgraded at Stifel on bexotegrast trial discontinuation - MSN
Pliant stock downgraded at Stifel trial discontinuation (PLRX:NASDAQ) - Seeking Alpha
This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Stifel Downgrades Pliant Therapeutics to Hold From Buy, Adjusts Price Target to $3 From $32 - Marketscreener.com
Needham Downgrades Pliant Therapeutics to Hold From Buy -March 04, 2025 at 08:28 am EST - Marketscreener.com
Pliant Therapeutics: Hold Rating Maintained Amid Trial Discontinuation and Adjusted Financial Outlook - TipRanks
RBC Cuts Price Target on Pliant Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk - Marketscreener.com
Pliant Therapeutics Reports Q4 2024 Results and Updates - MSN
Pliant Therapeutics price target lowered to $1.50 from $4 at Citi - TipRanks
Citi cuts Pliant Therapeutics stock target to $1.50, maintains neutral By Investing.com - Investing.com Canada
Cautious Hold Rating on Pliant Therapeutics Amid Uncertainty Over Bexotegrast Trial and Financial Outlook - TipRanks
Citi cuts Pliant Therapeutics stock target to $1.50, maintains neutral - Investing.com India
Hold Rating on Pliant Therapeutics Amidst BEACON-IPF Study Discontinuation and Uncertainty in Pipeline Prioritization - TipRanks
Pliant Therapeutics reinstated with a Neutral at Cantor Fitzgerald - TipRanks
Cantor Fitzgerald reinstates Pliant Therapeutics stock with neutral rating - Investing.com India
Cantor Fitzgerald reinstates Pliant Therapeutics stock with neutral rating By Investing.com - Investing.com UK
Pliant Therapeutics (NASDAQ:PLRX) Lowered to “Hold” Rating by Stifel Nicolaus - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Lowered to Market Perform Rating by Leerink Partners - Defense World
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis - GlobeNewswire
Pliant Therapeutics shares rise on better-than-expected Q4 earnings - Investing.com
Pliant Therapeutics shares rise on better-than-expected Q4 earnings By Investing.com - Investing.com Australia
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results - GlobeNewswire
Pliant's IPF Trial Halted on Safety Concerns: What's Next for Their $357M Pipeline? - StockTitan
Stifel cuts Pliant Therapeutics stock rating to hold, target to $3 By Investing.com - Investing.com South Africa
Pliant ends late-stage pulmonary fibrosis trial amid safety concerns - FirstWord Pharma
Leerink cuts Pliant Therapeutics stock rating after trial halt - Investing.com India
Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder - Benzinga India
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc.PLRX - PR Newswire
Leerink downgrades Pliant Therapeutics after trial discontinuation - TipRanks
Finanzdaten der Pliant Therapeutics Inc-Aktie (PLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.39%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):